Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

@article{Hodder2010PatientreportedOI,
  title={Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.},
  author={Sally L Hodder and Karam Mounzer and Edwin Dejesus and Robab Ebrahimi and Kristy Grimm and Stephen Esker and Janet Ecker and Awny Farajallah and John F. Flaherty},
  journal={AIDS patient care and STDs},
  year={2010},
  volume={24 2},
  pages={
          87-96
        }
}
A randomized, open-label, multicenter study was conducted to evaluate the therapeutic switch to a single-tablet formulation of efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) among virologically suppressed, HIV-1-infected subjects. Eligible subjects on stable antiretroviral therapy (ART) with HIV-1 RNA less than 200 copies per milliliter for 3 months or more were stratified by prior protease inhibitor (PI)- or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

Similar Papers

Loading similar papers…